Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal

Yusimry Biosimilar Divested To Hong Kong King-Friend For $40m Upfront

Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.

Investing in new business while divesting in old industry with an old tree shaped as a finance pie chart graph funding a green tree
• Source: Shutterstock

Meitheal Pharmaceuticals has ushered in what it believes is a “pivotal moment,” picking up its fifth biosimilar product and the first one on the market after gaining the exclusive US commercial rights to Coherus BioSciences’ Yusimry (adalimumab-aqvh) biosimilar to Humira.

The US-based injectables specialist’s parent company, Hong Kong King-Friend (HKF), has paid $40m upfront to Coherus for the worldwide rights...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

ViiV Extends Voluntary License For Long-Acting Cabotegravir As HIV Treatment

 

The Medicines Patent Pool’s extended voluntary license to produce long-acting cabotegravir to treat HIV is a win for patients living in LMICs, as the WHO updated its guidance to recommend it as an alternative treatment option.

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By 

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

More from Business